15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Regenxbio Inc, 9 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $12.00 to $50.00 (about 4.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $24.50 sits 155% above the current $9.59. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.97 next quarter toward $-2.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy990%
Hold110%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Regenxbio Inc.
As of Jul, 9 of 10 firms rate RGNX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RGNX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.97
Range $-1.63 – $0.32 · 7 analysts · -19% YoY
Next period, 7 analysts expect Regenxbio Inc to earn $-0.97 a share (range $-1.63 – $0.32), versus $-1.20 a year earlier. Full-year consensus is $-2.79, growing to $-2.54 the year after.
REVENUE · NEXT QUARTER
$46.0M
Range $11.9M – $131.9M · 7 analysts · +55% YoY
Revenue is expected to reach $46.0M (range $11.9M – $131.9M), +54.5% year-over-year. Full-year consensus is $237.9M, rising to $247.5M next year.
Top analysts covering Regenxbio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RGNX.
#1
Daniil Gataulin
Chardan Capital · Rank #36
Buy
$50.00+421.4% to target
Overall win rate
55%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$26.00+171.1% to target
Overall win rate
34%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$34.00+254.5% to target
Overall win rate
37%
+ Follow
#4
Luca Issi
RBC Capital
Buy
$19.00+98.1% to target
Coverage
—
+ Follow
#5
Paul Choi
Goldman Sachs
Hold
$10.00+4.3% to target
Coverage
—
+ Follow
RGNX stock forecast FAQ
What is RGNX's average 12-month price target?+
The 10 analysts with a live target average $24.50 for Regenxbio Inc over the next 12 months, ranging from a $50.00 high to a $12.00 low.
Is RGNX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 9 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RGNX?+
The Street-high target is $50.00 (Chardan Capital), and the Street-low is $12.00 (Barclays). The average of all 10 active targets is $24.50.
How many Wall Street analysts cover RGNX?+
10 analysts have an active rating on Regenxbio Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering RGNX?+
Among analysts who currently cover RGNX, Daniil Gataulin of Chardan Capital has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $50.00 target.
What is Regenxbio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.97 per share (range $-1.63 – $0.32) across 7 analysts. Full-year EPS is projected at $-2.79, rising to $-2.54 the following year.
How much revenue is Regenxbio Inc expected to report next quarter?+
Consensus revenue is $46.0M (range $11.9M – $131.9M). Full-year revenue is projected at $237.9M, growing to $247.5M next year.
Have analysts been upgrading or downgrading RGNX lately?+
As of Jul, 9 of 10 firms rate RGNX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RGNX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
